NASDAQ:ALNY - Alnylam Pharmaceuticals Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $219.47
Forecasted Upside: 48.04 %
Number of Analysts: 18
Breakdown:
0 Sell Ratings
4 Hold Ratings
14 Buy Ratings
0 Strong Buy Ratings

^$148.25 As of 07/1/2022 04:59 PM ET

▲ +2.4 (1.65%)

1 month | 3 months | 12 months

Get New Alnylam Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ALNY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALNY

^$219.47

▲ +48.04% Upside Potential

This price target is based on 18 analysts offering 12 month price targets for Alnylam Pharmaceuticals in the last 3 months. The average price target is $219.47, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 48.04% upside from the last price of $148.25.

Current Consensus is Buy

The current consensus among 18 investment analysts is to buy stock in Alnylam Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
12 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

1/10/2021

0 strong buy ratings
12 buy ratings
6 hold ratings
1 sell ratings

Ratings as of

4/10/2021

0 strong buy ratings
10 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

7/9/2021

0 strong buy ratings
10 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

10/7/2021

0 strong buy ratings
13 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

1/5/2022

0 strong buy ratings
13 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

4/5/2022

0 strong buy ratings
13 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

6/4/2022

0 strong buy ratings
14 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

7/4/2022

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
6/27/2022	Guggenheim	Downgrade	Buy ➝ Neutral		Low
6/16/2022	Needham & Company LLC	Initiated Coverage	Buy	$205.00	High
6/15/2022	SVB Leerink	Boost Price Target	Market Perform	$96.00 ➝ $98.00	High
6/7/2022	William Blair	Initiated Coverage	Outperform		Medium
5/2/2022	HC Wainwright	Boost Price Target		$400.00 ➝ $430.00	Medium
4/29/2022	Citigroup	Lower Price Target		$223.00 ➝ $211.00	High
4/25/2022	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$210.00 ➝ $178.00	Medium
4/12/2022	HC Wainwright	Boost Price Target	Buy	$350.00 ➝ $400.00	Medium
4/6/2022	Oppenheimer	Reiterated Rating	Outperform	$205.00	Low
3/24/2022	Stifel Nicolaus	Reiterated Rating	Buy	$215.00	Low
2/28/2022	Citigroup	Initiated Coverage	Buy	$223.00	High
2/23/2022	Morgan Stanley	Lower Price Target	Overweight	$215.00 ➝ $210.00	Low
2/11/2022	Chardan Capital	Reiterated Rating	Buy	$200.00	Medium
2/11/2022	SVB Leerink	Lower Price Target	Market Perform	$109.00 ➝ $103.00	Medium
2/3/2022	Guggenheim	Upgrade	Neutral ➝ Buy	$170.00	Low
1/28/2022	SVB Leerink	Boost Price Target	Market Perform	$108.00 ➝ $109.00	High
1/20/2022	HC Wainwright	Boost Price Target	Buy	$250.00 ➝ $350.00	High
1/18/2022	Morgan Stanley	Lower Price Target	Overweight	$226.00 ➝ $215.00	High
1/3/2022	Bank of America	Reiterated Rating	Buy ➝ Buy	$211.00	Medium
1/3/2022	Piper Sandler	Upgrade	Neutral ➝ Overweight	$181.00 ➝ $208.00	Low
12/30/2021	Oppenheimer	Reiterated Rating	Outperform	$200.00	Low
12/1/2021	SVB Leerink	Reiterated Rating	Hold		Medium
11/22/2021	Needham & Company LLC	Boost Price Target	Buy	$180.00 ➝ $205.00	High
11/22/2021	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$273.00	High
11/22/2021	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$144.00 ➝ $225.00	High
11/1/2021	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$200.00	Low
10/31/2021	BMO Capital Markets	Reiterated Rating	Hold ➝ Neutral		Medium
10/29/2021	Morgan Stanley	Lower Price Target	Overweight	$242.00 ➝ $226.00	High
10/29/2021	Chardan Capital	Boost Price Target	Buy	$190.00 ➝ $200.00	High
10/29/2021	Cantor Fitzgerald	Boost Price Target	Overweight	$202.00 ➝ $275.00	Low
10/28/2021	SVB Leerink	Boost Price Target	Market Perform	$104.00 ➝ $108.00	High
10/18/2021	SVB Leerink	Reiterated Rating	Market Perform		Low
10/12/2021	Morgan Stanley	Boost Price Target	Overweight	$234.00 ➝ $242.00	Low
10/4/2021	UBS Group	Upgrade	Neutral ➝ Buy	$141.00 ➝ $215.00	Low
8/27/2021	BMO Capital Markets	Boost Price Target	Neutral ➝ Market Perform	$174.00 ➝ $196.00	Medium
8/13/2021	HC Wainwright	Boost Price Target	Buy	$235.00 ➝ $250.00	High
8/4/2021	Chardan Capital	Reiterated Rating	Buy	$190.00	Medium
8/4/2021	Morgan Stanley	Boost Price Target	Overweight	$224.00 ➝ $234.00	High
8/4/2021	Barclays	Boost Price Target	Overweight	$196.00 ➝ $216.00	High
8/4/2021	Piper Sandler	Downgrade	Overweight ➝ Neutral	$45.00 ➝ $47.00	High
7/16/2021	Morgan Stanley	Boost Price Target	Overweight	$205.00 ➝ $224.00	High
4/30/2021	Morgan Stanley	Lower Price Target	Overweight	$206.00 ➝ $205.00	Low
4/20/2021	Needham & Company LLC	Reiterated Rating	Buy		Low
3/1/2021	Guggenheim	Reiterated Rating	Buy ➝ Neutral	$162.00	Low
2/22/2021	Guggenheim	Downgrade	Buy ➝ Neutral	$162.00	Medium
2/14/2021	Royal Bank of Canada	Reiterated Rating	Hold		Low
2/12/2021	Needham & Company LLC	Boost Price Target	Buy	$160.00 ➝ $180.00	Low
2/12/2021	Morgan Stanley	Boost Price Target	Overweight	$203.00 ➝ $206.00	Low
2/12/2021	Citigroup	Downgrade	Buy ➝ Neutral	$170.00 ➝ $175.00	Low
2/12/2021	Barclays	Boost Price Target	Overweight	$162.00 ➝ $196.00	Low
2/12/2021	HC Wainwright	Boost Price Target	Buy	$225.00 ➝ $235.00	Low
1/25/2021	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$185.00 ➝ $185.00	High
1/13/2021	Cowen	Boost Price Target	In-Line ➝ Outperform	$154.00 ➝ $197.00	High
1/8/2021	HC Wainwright	Reiterated Rating	Buy	$225.00	High
12/21/2020	Royal Bank of Canada	Lower Price Target	Sector Perform	$150.00 ➝ $144.00	Medium
12/17/2020	Piper Sandler	Boost Price Target	Overweight	$169.00 ➝ $181.00	Low
11/25/2020	BMO Capital Markets	Boost Price Target		$182.00 ➝ $183.00	Low
11/25/2020	Morgan Stanley	Boost Price Target	Overweight	$200.00 ➝ $203.00	Low
11/24/2020	SVB Leerink	Boost Price Target	Market Perform	$90.00 ➝ $91.00	Low
11/6/2020	Morgan Stanley	Boost Price Target	Overweight	$197.00 ➝ $200.00	High
10/15/2020	Bank of America	Lower Price Target	Buy	$160.00 ➝ $157.00	Low
10/12/2020	Chardan Capital	Reiterated Rating	Buy		Low
9/30/2020	Oppenheimer	Reiterated Rating	Hold	$156.00	Medium
9/30/2020	Berenberg Bank	Initiated Coverage	Hold	$145.00	Medium
9/8/2020	Citigroup	Initiated Coverage	Buy	$170.00 ➝ $170.00	Low
8/24/2020	HC Wainwright	Reiterated Rating	Buy		Low
8/11/2020	Oppenheimer	Downgrade	Outperform ➝ Market Perform	$162.00 ➝ $156.00	Low
8/7/2020	Morgan Stanley	Lower Price Target	Overweight	$199.00 ➝ $197.00	Low
8/7/2020	Chardan Capital	Reiterated Rating	Buy		Low
8/7/2020	SVB Leerink	Boost Price Target	Market Perform	$89.00 ➝ $90.00	Low
7/20/2020	BMO Capital Markets	Boost Price Target	Outperform	$173.00 ➝ $196.00	High
7/15/2020	Morgan Stanley	Boost Price Target	Overweight	$162.00 ➝ $199.00	Low
5/28/2020	UBS Group	Boost Price Target	Neutral	$111.00 ➝ $122.00	Low
5/12/2020	Royal Bank of Canada	Initiated Coverage	Sector Perform	$150.00	Medium
5/7/2020	BMO Capital Markets	Boost Price Target	Outperform	$145.00 ➝ $171.00	Low
5/7/2020	Oppenheimer	Boost Price Target	Outperform	$140.00 ➝ $162.00	High
5/7/2020	Morgan Stanley	Boost Price Target	Overweight	$148.00 ➝ $162.00	High
5/7/2020	Barclays	Boost Price Target	Overweight	$143.00 ➝ $156.00	High
5/7/2020	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$133.00 ➝ $137.00	High
5/6/2020	Needham & Company LLC	Boost Price Target	Buy	$135.00 ➝ $160.00	High
4/24/2020	Evercore ISI	Initiated Coverage	Buy	$160.00	Low
4/14/2020	Needham & Company LLC	Reiterated Rating	Buy	$135.00	High
4/14/2020	Cantor Fitzgerald	Boost Price Target		$195.00 ➝ $202.00	Low
4/14/2020	Piper Sandler	Lower Price Target		$147.00 ➝ $142.00	Medium
4/14/2020	Nomura Securities	Lower Price Target	Reduce	$75.00 ➝ $74.00	Medium
4/13/2020	Oppenheimer	Reiterated Rating	Buy	$140.00	Medium
3/19/2020	Berenberg Bank	Initiated Coverage	Buy	$200.00	Low
3/5/2020	Cowen	Reiterated Rating	Buy		Medium
3/3/2020	Piper Sandler	Reiterated Rating	Buy	$155.00	N/A
2/11/2020	Nomura Securities	Boost Price Target	Reduce	$62.00 ➝ $75.00	Medium
2/9/2020	Cowen	Reiterated Rating	Buy	$154.00	High
2/7/2020	Evercore ISI	Initiated Coverage	Buy	$145.00	High
2/7/2020	Morgan Stanley	Lower Price Target	Overweight	$150.00 ➝ $148.00	Medium
2/7/2020	Chardan Capital	Reiterated Rating	Buy		High
2/7/2020	Needham & Company LLC	Reiterated Rating	Buy		High
12/19/2019	Chardan Capital	Boost Price Target	Buy	$150.00 ➝ $190.00	Low
12/18/2019	Nomura Securities	Reiterated Rating	Sell	$62.00	Low
12/18/2019	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$159.00 ➝ $176.00	Medium
12/17/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$145.00 ➝ $155.00	Medium
12/17/2019	Morgan Stanley	Boost Price Target	Overweight	$141.00 ➝ $150.00	High
11/27/2019	Cantor Fitzgerald	Boost Price Target		$150.00 ➝ $159.00	Low
11/21/2019	BMO Capital Markets	Boost Price Target	Outperform	$128.00 ➝ $138.00	High
11/21/2019	Barclays	Boost Price Target	Overweight	$125.00 ➝ $131.00	High
11/21/2019	Needham & Company LLC	Initiated Coverage	Buy	$135.00	Low
11/21/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$150.00 ➝ $159.00	Low
11/19/2019	Oppenheimer	Initiated Coverage	Outperform	$128.00 ➝ $128.00	High
11/18/2019	Cowen	Reiterated Rating	Buy	$120.00	High
11/13/2019	Bank of America	Initiated Coverage	Buy	$110.00	Low
10/31/2019	Needham & Company LLC	Reiterated Rating	Buy	$135.00	Low
10/8/2019	Nomura Securities	Set Price Target	Sell	$62.00	Low
9/10/2019	Piper Jaffray Companies	Set Price Target	Buy	$145.00	High
9/4/2019	UBS Group	Boost Price Target	Neutral	$95.00 ➝ $96.00	Low
9/3/2019	Stifel Nicolaus	Set Price Target	Buy	$116.00	Low
9/3/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$142.00 ➝ $145.00	Medium
8/26/2019	Piper Jaffray Companies	Set Price Target	Buy	$142.00	Low
8/7/2019	Barclays	Reiterated Rating	Buy	$125.00	High
8/7/2019	Morgan Stanley	Lower Price Target	Overweight	$126.00 ➝ $124.00	High
8/7/2019	Cowen	Lower Price Target	Outperform	$147.00 ➝ $120.00	High
5/23/2019	The Goldman Sachs Group	Reiterated Rating	Neutral ➝ Neutral	$80.00	Medium
5/2/2019	Morgan Stanley	Set Price Target	Buy	$126.00	High
5/2/2019	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$126.00 ➝ $128.00	High
4/15/2019	Stifel Nicolaus	Boost Price Target	Buy ➝ Buy	$110.00 ➝ $116.00	Low
4/15/2019	Cantor Fitzgerald	Boost Price Target	Overweight ➝ Overweight	$135.00 ➝ $138.00	Low
4/15/2019	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$119.00 ➝ $126.00	Low
4/11/2019	Evercore ISI	Initiated Coverage	Outperform	$120.00	Medium
4/9/2019	SVB Leerink	Boost Price Target	Market Perform	$90.00	Medium
4/9/2019	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$106.00 ➝ $119.00	High
4/9/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$135.00	Medium
4/9/2019	Chardan Capital	Reiterated Rating	Buy	$150.00	Medium
3/6/2019	Cowen	Reiterated Rating	Buy		Low
3/6/2019	Evercore ISI	Upgrade	In-Line ➝ Outperform		Low
3/5/2019	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$122.00	Low
2/8/2019	Needham & Company LLC	Reiterated Rating	Buy	$135.00	High
2/8/2019	BMO Capital Markets	Lower Price Target	Outperform	$106.00	High
2/7/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$135.00	High
1/23/2019	UBS Group	Initiated Coverage	Neutral ➝ Neutral	$87.00	Low
1/15/2019	Piper Jaffray Companies	Lower Price Target	Overweight	$152.00	Low
12/17/2018	Guggenheim	Initiated Coverage	Buy	$105.00	Medium
12/7/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$135.00	High
11/27/2018	SVB Leerink	Initiated Coverage	Market Perform	$63.00	Low
11/8/2018	Cantor Fitzgerald	Reiterated Rating	Buy		N/A
10/18/2018	BMO Capital Markets	Reiterated Rating	Buy		High
10/16/2018	BMO Capital Markets	Lower Price Target	Outperform ➝ Outperform	$125.00 ➝ $124.00	Medium
10/1/2018	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$135.00	Low
9/28/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$93.00 ➝ $87.00	High
9/13/2018	Needham & Company LLC	Reiterated Rating	Buy	$152.00	Medium
9/13/2018	Stifel Nicolaus	Reiterated Rating	Buy	$123.00 ➝ $117.00	Medium
9/4/2018	Cowen	Reiterated Rating	Buy	$147.00	High
8/28/2018	JMP Securities	Set Price Target	Buy	$198.00	Medium
8/27/2018	Needham & Company LLC	Set Price Target	Buy	$152.00	Low
8/13/2018	B. Riley	Boost Price Target	Buy ➝ Buy	$210.00 ➝ $230.00	High
8/13/2018	Nomura Securities	Lower Price Target	Reduce ➝ Reduce	$86.00 ➝ $73.00	High
8/13/2018	Morgan Stanley	Set Price Target	Equal Weight ➝ Hold	$99.00 ➝ $93.00	High
8/13/2018	Needham & Company LLC	Reiterated Rating	Buy	$152.00	High
8/13/2018	Cowen	Lower Price Target	Outperform ➝ Outperform	$157.00 ➝ $147.00	High
8/13/2018	Stifel Nicolaus	Reiterated Rating	Sell ➝ Buy	$125.00 ➝ $123.00	Medium
8/13/2018	The Goldman Sachs Group	Downgrade	Conviction-Buy ➝ Buy		Low
8/13/2018	BMO Capital Markets	Lower Price Target	Outperform ➝ Outperform	$127.00 ➝ $125.00	High
8/6/2018	Stifel Nicolaus	Upgrade	Hold ➝ Buy	$95.00 ➝ $125.00	Low
8/6/2018	Jefferies Financial Group	Reiterated Rating	Buy	$149.00	Low
8/6/2018	JMP Securities	Set Price Target	Buy	$207.00	Medium
8/3/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$107.00 ➝ $99.00	High
8/3/2018	Chardan Capital	Reiterated Rating	Buy	$180.00	High
8/3/2018	BMO Capital Markets	Reiterated Rating	Buy	$127.00	High
8/2/2018	Cowen	Reiterated Rating	Buy	$157.00	High
7/23/2018	Piper Jaffray Companies	Reiterated Rating	Overweight		Low
6/27/2018	Piper Jaffray Companies	Lower Price Target	Overweight	$182.00 ➝ $160.00	Medium
5/7/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$118.00	Medium
5/4/2018	BMO Capital Markets	Lower Price Target	Outperform ➝ Outperform	$160.00 ➝ $134.00	N/A
5/4/2018	Stifel Nicolaus	Lower Price Target	Hold ➝ Hold	$107.00 ➝ $95.00	High
4/2/2018	B. Riley	Reiterated Rating	Buy	$200.00	Medium
4/2/2018	Jefferies Financial Group	Reiterated Rating	Buy		High
3/28/2018	Evercore ISI	Initiated Coverage	In ➝ line	$131.18 ➝ $143.00	Medium
3/26/2018	JMP Securities	Boost Price Target	Mkt Outperform ➝ Outperform	$169.00 ➝ $207.00	Low
3/13/2018	Credit Suisse Group	Boost Price Target	Outperform ➝ Outperform	$151.00 ➝ $154.00	High
2/16/2018	B. Riley	Lower Price Target	Buy ➝ Buy	$205.00 ➝ $200.00	Medium
2/9/2018	Credit Suisse Group	Set Price Target	Buy	$151.00	Low
2/9/2018	Jefferies Financial Group	Set Price Target	Buy	$156.00	Low
2/9/2018	Nomura Securities	Boost Price Target	Sell	$86.00	Low
2/9/2018	BMO Capital Markets	Lower Price Target	Outperform ➝ Outperform	$165.00 ➝ $160.00	Medium
2/9/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$128.00 ➝ $118.00	Medium
1/25/2018	SVB Leerink	Boost Price Target	Market Perform ➝ Market Perform	$132.00 ➝ $135.00	Low
1/19/2018	B. Riley	Reiterated Rating	Buy	$205.00	Low
1/19/2018	Chardan Capital	Reiterated Rating	Buy		Low
1/8/2018	B. Riley	Reiterated Rating	Buy ➝ Buy	$220.00 ➝ $205.00	Medium
1/7/2018	Piper Jaffray Companies	Reiterated Rating	Buy	$182.00	Medium
12/15/2017	The Goldman Sachs Group	Upgrade	Buy ➝ Conviction-Buy		High
12/11/2017	B. Riley	Reiterated Rating	Buy	$220.00	Low
11/17/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$182.00	N/A
11/9/2017	Cowen	Reiterated Rating	Buy	$151.00	N/A
11/9/2017	Morgan Stanley	Boost Price Target	Equal Weight	$101.00 ➝ $130.00	N/A
11/9/2017	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight		N/A
11/8/2017	B. Riley	Lower Price Target	Buy	$220.00	N/A
11/8/2017	Barclays	Boost Price Target	Overweight	$127.00 ➝ $158.00	N/A
11/3/2017	Credit Suisse Group	Boost Price Target	Outperform	$123.00 ➝ $151.00	N/A
11/3/2017	Cowen	Reiterated Rating	Outperform	$117.00 ➝ $151.00	N/A
11/3/2017	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $152.00	N/A
11/2/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$188.00 ➝ $14.71	N/A
11/1/2017	B. Riley	Initiated Coverage	Buy	$150.00 ➝ $240.00	N/A
10/30/2017	FBR & Co.	Initiated Coverage	Buy ➝ Buy	$150.00	N/A
10/2/2017	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$62.00 ➝ $163.00	Medium
9/26/2017	Jefferies Financial Group	Boost Price Target	Positive ➝ Buy	$102.00 ➝ $130.00	Low
9/25/2017	Chardan Capital	Reiterated Rating	Buy	$124.00	Low
9/22/2017	BMO Capital Markets	Reiterated Rating	Outperform	$99.00 ➝ $134.00	Low
9/21/2017	LADENBURG THALM/SH SH	Reiterated Rating	Buy	$90.00 ➝ $146.00	Low
9/21/2017	Sanford C. Bernstein	Reiterated Rating	Outperform ➝ Buy	$94.00 ➝ $135.00	Low
9/20/2017	Stifel Nicolaus	Reiterated Rating	Hold	$56.00 ➝ $83.00	Low
9/20/2017	Cowen	Reiterated Rating	Outperform	$93.00 ➝ $117.00	Low
9/20/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$110.00 ➝ $116.00	Low
9/20/2017	Needham & Company LLC	Boost Price Target	Buy ➝ Buy	$85.00 ➝ $125.00	Low
9/20/2017	JMP Securities	Boost Price Target	Outperform	$101.00 ➝ $128.00	Low
9/18/2017	Jefferies Financial Group	Reiterated Rating	Buy	$102.00	Low
9/15/2017	Nomura Instinet	Initiated Coverage	Reduce ➝ Reduce	$56.00	Low
9/14/2017	Nomura Securities	Initiated Coverage	Reduce	$56.00	High
9/11/2017	Chardan Capital	Reiterated Rating	Buy		High
9/8/2017	SVB Leerink	Reiterated Rating	Market Perform	$83.00 ➝ $72.00	Low
9/7/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$126.00 ➝ $110.00	Low
9/7/2017	Needham & Company LLC	Reiterated Rating	Buy	$98.00 ➝ $85.00	Low
9/7/2017	Barclays	Reiterated Rating	Equal Weight ➝ Overweight	$80.00 ➝ $105.00	High
9/6/2017	BMO Capital Markets	Reiterated Rating	Outperform	$105.00 ➝ $99.00	Low
8/25/2017	Jefferies Financial Group	Set Price Target	Buy	$102.00	Low
8/11/2017	Credit Suisse Group	Reiterated Rating	Buy	$96.00	Low
8/10/2017	Stifel Nicolaus	Reiterated Rating	Buy	$47.00 ➝ $56.00	Medium
8/10/2017	Chardan Capital	Reiterated Rating	Buy	$131.00 ➝ $124.00	Medium
8/10/2017	Morgan Stanley	Boost Price Target	Equal Weight	$46.00 ➝ $50.00	Medium
8/10/2017	Barclays	Boost Price Target	Equal Weight	$50.00 ➝ $70.00	High
7/27/2017	Sanford C. Bernstein	Initiated Coverage	Outperform	$99.00	High
7/17/2017	LADENBURG THALM/SH SH	Set Price Target	Buy ➝ Buy	$80.00 ➝ $90.00	Low
7/11/2017	Cowen	Reiterated Rating	Buy	$100.00	Low
7/11/2017	Credit Suisse Group	Set Price Target	Buy	$96.00	Low
7/10/2017	Morgan Stanley	Reiterated Rating	Equal Weight		Low
7/10/2017	Needham & Company LLC	Reiterated Rating	Buy	$98.00	Low
7/10/2017	Chardan Capital	Reiterated Rating	Buy	$110.00 ➝ $131.00	High

(Data available from 7/5/2017 forward)

News Sentiment Rating

0.29 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

0 very positive mentions
7 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

12/6/2021

8 very positive mentions
10 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

1/5/2022

2 very positive mentions
17 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

2/4/2022

0 very positive mentions
12 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

3/6/2022

1 very positive mentions
12 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

4/5/2022

2 very positive mentions
7 positive mentions
6 negative mentions
2 very negative mentions

Mentions as of

5/5/2022

0 very positive mentions
7 positive mentions
6 negative mentions
1 very negative mentions

Mentions as of

6/4/2022

4 very positive mentions
14 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

7/4/2022

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $148.25

$144.67

$148.40

50 Day Range

MA: $134.91

$120.42

$155.00

52 Week Range

Now: $148.25

$117.58

$212.00

Volume

29,478 shs

Average Volume

978,264 shs

Market Capitalization

$17.91 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Alnylam Pharmaceuticals?: The following Wall Street sell-side analysts have issued research reports on Alnylam Pharmaceuticals in the last year: Bank of America Co., Barclays PLC, BMO Capital Markets, Cantor Fitzgerald, Chardan Capital, Citigroup Inc., Guggenheim, HC Wainwright, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., UBS Group AG, and William Blair.
View the latest analyst ratings for ALNY.
What is the current price target for Alnylam Pharmaceuticals?: 0 Wall Street analysts have set twelve-month price targets for Alnylam Pharmaceuticals in the last year. Their average twelve-month price target is $219.47, suggesting a possible upside of 48.0%.
View the latest price targets for ALNY.
What is the current consensus analyst rating for Alnylam Pharmaceuticals?: Alnylam Pharmaceuticals currently has 4 hold ratings and 14 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ALNY will outperform the market and that investors should add to their positions of Alnylam Pharmaceuticals.
View the latest ratings for ALNY.
What other companies compete with Alnylam Pharmaceuticals?: Other companies that are similar to Alnylam Pharmaceuticals include Amgen, Gilead Sciences, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Seagen, Biogen, Incyte, BioMarin Pharmaceutical, United Therapeutics, Neurocrine Biosciences, Repligen, Exact Sciences, Exelixis, Halozyme Therapeutics and Ionis Pharmaceuticals. Learn More about companies similar to Alnylam Pharmaceuticals.
How do I contact Alnylam Pharmaceuticals' investor relations team?: Alnylam Pharmaceuticals' physical mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company's listed phone number is (617) 551-8200 and its investor relations email address is [email protected] The official website for Alnylam Pharmaceuticals is www.alnylam.com. Learn More about contacing Alnylam Pharmaceuticals investor relations.

NASDAQ:ALNY - Alnylam Pharmaceuticals Stock Price Target and Predictions

Analyst Price Target for ALNY

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.29 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Alnylam Pharmaceuticals?

What is the current price target for Alnylam Pharmaceuticals?

What is the current consensus analyst rating for Alnylam Pharmaceuticals?

What other companies compete with Alnylam Pharmaceuticals?

How do I contact Alnylam Pharmaceuticals' investor relations team?